Literature DB >> 7508115

Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia.

R B Myers1, J E Kudlow, W E Grizzle.   

Abstract

The present immunohistochemical study examines the expression of TGF alpha, EGF, and the EGF receptor in prostatic tissues obtained from patients with either benign prostatic hyperplasia (BPH) or adenocarcinoma of the prostate. Frozen sections were cut at 5 microns and were incubated with monoclonal antibodies directed against TGF alpha, EGF, or the EGF receptor. The remainder of the staining procedure was performed with an avidin-biotin-complex peroxidase procedure. Strong TGF alpha expression was not detected in any of the 15 BPH specimens examined or in the normal/hyperplastic tissue intermixed within the adenocarcinomas. In contrast, malignant cells in 9 of 11 adenocarcinomas strongly expressed TGF alpha. EGF reactivity was observed in both hyperplastic and malignant epithelial tissues. EGF receptor expression was strongest along the basal aspects of cells of normal or hyperplastic glands. Although most malignant cells also were positive for the EGF receptor the level of staining was less than that observed in cells forming normal or hyperplastic glands. These results suggest that EGF and the EGF receptor may be components of an autocrine/paracrine regulatory pathway involved in hyperplastic and/or malignant disease of the prostate. The finding that TGF alpha is expressed only in malignant cells suggests that TGF alpha may represent a locally active autocrine regulator of malignant prostate cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508115

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  12 in total

Review 1.  Targeting signal transduction for disease therapy.

Authors:  A Levitzki
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.064

2.  EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells.

Authors:  T Turner; P Chen; L J Goodly; A Wells
Journal:  Clin Exp Metastasis       Date:  1996-09       Impact factor: 5.150

3.  [Clinicopathological and molecular characteristics of Epstein-Barr virus associated gastric cancer: a single center large sample case investigation].

Authors:  Y Yang; Y Q Liu; X H Wang; K Ji; Z W Li; J Bai; A R Yang; Y Hu; H B Han; Z Y Li; Z D Bu; X J Wu; L H Zhang; J F Ji
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-06-18

Review 4.  Growth factors as mediators of androgen action during the development of the male urogenital tract.

Authors:  G R Cunha; B Foster; A Thomson; Y Sugimura; N Tanji; M Tsuji; N Terada; P W Finch; A A Donjacour
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 5.  At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone.

Authors:  John Foley; Nicole Nickerson; David J Riese; Peter C Hollenhorst; Gwendolen Lorch; Anne M Foley
Journal:  Odontology       Date:  2012-06-10       Impact factor: 2.634

6.  EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.

Authors:  Alyse M DeHaan; Natalie M Wolters; Evan T Keller; Kathleen M Woods Ignatoski
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

7.  Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer.

Authors:  Lutz Trojan; Daniel Thomas; Thomas Knoll; Rainer Grobholz; Peter Alken; Maurice Stephan Michel
Journal:  Urol Res       Date:  2004-05

Review 8.  Prostate cancer progression. Implications of histopathology.

Authors:  J L Ware
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

Review 9.  Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate.

Authors:  E R Sherwood; C Lee
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 10.  Immunopathological prognostic and predictive factors in prostate cancer.

Authors:  E Sivridis; S Touloupidis; A Giatromanolaki
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.